A Groundbreaking ‘Win’ at the United Nations Commission on Narcotic Drugs

On March 14-22, 2024, the UN Commission on Narcotic Drugs (CND) held its 67th annual session in Vienna, Austria. The session saw a landmark vote that may have important repercussions for drug policy, in Latin America and elsewhere.

 

The commission approved a U.S.-led resolution encouraging countries to implement “harm reduction” measures to respond to drug overdoses and to protect public health.

 

The vote marks a major breakthrough in civil society’s decades-long advocacy to center harm reduction, especially since the U.S. government has a history of blocking all such resolutions, and since the Commission has a longstanding tradition of enactment by a “Vienna Consensus” without votes.

 

This episode features three guests who helped lead civil society’s robust participation at the CND:

 

• Ann Fordham, executive director of International Drug Policy Consortium (IDPC)

• Lisa Sanchez, executive director of México Unido Contra la Delincuencia (MUCD)

• John Walsh, director for drug policy and the Andes at WOLA

 

The three experts underscore that while the vote on this resolution was a major win in the civil society-led harm reduction fight, it is just one milestone along a longer journey. The fight must continue to ensure this sets the foundation for an international drug policy that truly prioritizes protecting people, views drug addiction as a public health and not a national security issue, and moves away from the normative framework of achieving a “drug free society” through punitive measures and prohibition.

 

“The prohibition regime has tried to make itself inevitable and ‘forever,’ and that’s not the case… There's no reason to think that it needs to last forever. In fact, as we said, it was a misfit from the very beginning,” says John Walsh. “Drug use has always existed, it always will. To suggest that we're going to create a ‘drug-free world’ is not only futile, but it's downright dangerous because of its consequences… I think this is an opening to think more broadly about not just the UN drug policy space, but what governments need to do for the health, safety, and well-being of their populations.”